- Home
- CBLL vs ARVN Comparison
CBLL vs ARVN Comparison
Compare CBLL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBLL | ARVN |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.1M | 781.0M |
| IPO Year | 2024 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CBLL | ARVN |
|---|---|---|
| Price | $22.41 | $12.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 23 |
| Target Price | ★ $24.67 | $18.14 |
| AVG Volume (30 Days) | 553.7K | ★ 866.8K |
| Earning Date | 02-24-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $82,813,000.00 | ★ $312,300,000.00 |
| Revenue This Year | $37.43 | $11.17 |
| Revenue Next Year | $27.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 37.93 | ★ 93.86 |
| 52 Week Low | $10.01 | $5.90 |
| 52 Week High | $26.04 | $20.90 |
Technical Indicators
Market Signals| Indicator | CBLL | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 69.81 | 55.03 |
| Support Level | $20.39 | $11.01 |
| Resistance Level | $22.96 | $12.74 |
| Average True Range (ATR) | 0.97 | 0.51 |
| MACD | -0.22 | -0.07 |
| Stochastic Oscillator | 79.57 | 72.91 |
Price Performance
Historical ComparisonAbout CBLL CeriBell Inc.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.